• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • About
  • Our Products
    • Restoret
  • Team
EyeBio

EyeBio

  • Business Development
  • News
  • Contact

Developing a new generation of therapies to protect, restore, and improve vision

About Us

We created EyeBio to achieve a specific mission: to protect, restore, and improve vision for people living with eye diseases. Our work is urgent, because available therapies regularly fall short of improving vision or fail to provide durable, long-term solutions for patients.

EyeBio brings together an experienced team of leaders, innovators, and entrepreneurs to develop a new generation of therapies for eye diseases. We understand what it takes to establish a new standard of care in ophthalmology. Our co-founders, Dr. David Guyer and Dr. Anthony P. Adamis, created and led the company that introduced the first anti-vascular endothelial growth factor (anti-VEGF) therapy for patients with age-related macular degeneration (AMD).

Working with a team of investors from several of the world’s leading healthcare fund managers, including SV Health Investors, Samsara BioCapital, Jeito Capital, and MRL Ventures, EyeBio has amassed the resources to develop and deliver new therapeutic solutions to patients with eye diseases. Together, EyeBio’s senior leadership and investors comprise an experienced team with a sharp focus on innovation in ophthalmology therapy.

We’re just getting started

Driven by a spirit of discovery and innovation, EyeBio is building a broad and diverse pipeline of advanced therapies for eye diseases. We invite you to learn more about our mission, our research and development programs, and our people.

Restoret

Learn more about Restoret, our lead asset targeting the Wnt pathway to treat retinal diseases.

Learn More

The EyeBio Team

The EyeBio leadership team and board of directors have an unrivalled track record for developing ground-breaking ophthalmology therapies. The team’s deep experience and proven success in clinical development, combined with an extensive multinational clinical trial network, uniquely position EyeBio to efficiently and successfully advance new programs with the potential to redefine the treatment of eye diseases.  

Management Team

David Guyer, M.D.

Co-founder, President, & Chief Executive Officer

Read David Guyer, M.D.'sBio

Anthony P. Adamis, M.D.

Chief Scientific Officer

Read Anthony P. Adamis, M.D.'sBio

Jonathan Prenner, M.D.

Chief Medical Officer

Read Jonathan Prenner, M.D.'sBio

Sarah Milsom

Chief Operating Officer

Read Sarah Milsom'sBio

Loni Da Silva

Chief Regulatory Officer

Read Loni Da Silva'sBio

Keith Baker

Vice President of Clinical Development

Read Keith Baker'sBio

Jonathon Dines, Ph.D.

Finance Director

Read Jonathon Dines, Ph.D.'sBio

Mike Davies

Chemistry, Manufacturing, and Control (CMC) Lead, Drug Development

Read Mike Davies'sBio

Frances Betts

Global Head, Clinical Operations

Read Frances Betts'sBio

Laura Kupsch

Vice President of Quality Assurance

Read Laura Kupsch'sBio

Divya Chadha Manek, OBE

Director of Clinical Operations, Ex-US

Read Divya Chadha Manek, OBE'sBio

Eric Ng, Ph. D.

Senior Vice President of Biology

Read Eric Ng, Ph. D.'sBio

Paul Stephens, Ph.D.

Senior Vice President, Chemistry, Manufacturing, and Controls

Read Paul Stephens, Ph.D.'sBio

Board of Directors

Kate Bingham, DBE

Managing Partner, SV Health Investors
EyeBio Board Chair

Read Kate Bingham, DBE'sBio

Anthony P. Adamis, M.D.

Co-founder, Director & Chair of Advisory Board

Read Anthony P. Adamis, M.D.'sBio

Srinivas Akkaraju, M.D., Ph.D.

Founder and Managing General Partner, Samsara BioCapital

Read Srinivas Akkaraju, M.D., Ph.D.'sBio

Evelyn Harrison

SVP, Chief Clinical Operations Officer, Iveric Bio.

Read Evelyn Harrison'sBio

Mike Ross, Ph.D.

Managing Partner, SV Health Investors

Read Mike Ross, Ph.D.'sBio

Andreas Wallnoefer, Ph.D.

Partner & Investor, Jeito Capital

Read Andreas Wallnoefer, Ph.D.'sBio

News

March 6, 2023

EyeBio Announces First Asset in Innovative Pipeline of Retinal Disease Treatments and Appoints Industry Leaders to Executive Team

Read More

February 22, 2022

EyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies

Read More

Have any press inquiries or looking for more information?

Contact Us

Footer

Contact Us

Please fill out the brief form below with any questions or inquiries, and a member of our team will connect with you soon.

Business Development

EyeBio is bringing disruptive innovation to the field of ophthalmology. We actively seek to expand our pipeline of promising investigational therapies, and we welcome inquiries regarding in-licensing and acquisition of assets into our portfolio.

To learn more, please contact Sarah Milsom, Chief Operating Officer of EyeBio, at s.milsom@nulleyebiotech.com.

Privacy Policy
Terms of Use
Cookie Policy
Accessibility Statement

EyeBio

LinkedIn

Copyright © 2022 EyeBio

logo
  • About
  • Our Products
    • Restoret
  • Team
  • Business Development
  • News
  • Contact